rs CYP2C A>G G AA -/- rs CYP2C9 A6326C C AA -/-
|
|
|
- Lynette Merritt
- 8 years ago
- Views:
Transcription
1 Liver Detox - Phase I (Figure 1) rs CYP1A1*2C A4889G C CT +/- rs CYP1A1*4 C2453A T GG -/- rs CYP1A2*1F A AG +/- rs CYP1A2*1F C164A C AA -/- rs CYP1A2*1K -739T>G G TT -/- rs CYP1A2*3 D348N A GG -/- rs CYP1A2*6 R431W T CC -/- rs CYP1B C>T T CC -/- rs CYP1B1 A119S A CC -/- rs CYP1B1 L432V C GG -/- rs CYP1B1 N453S T TT +/+ rs10012 CYP1B1 R48G G CG +/- rs CYP1B1 T241A A AA +/+ rs CYP2A6 T1412C G AA -/- rs CYP2A6 V365M T CC -/- rs CYP2A6*2 A1799T T AA -/- rs CYP2B6 A136G G AA -/- rs CYP2B6 C1132T T CC -/- rs CYP2B6 C26570T T CC -/- rs CYP2B6 I328T C TT -/- rs CYP2B6 Q172H T GG -/- rs CYP2B6 R22C T CC -/- rs CYP2B6 R487C T CC -/- rs CYP2B6 T1421C C TT -/- rs CYP2B6 T20715C C TT -/- rs CYP2B6 T23499C T CT +/- rs CYP2C19 C1418T T CC -/- rs CYP2C19 C5709T T CT +/- rs CYP2C19 T106C C CT +/- rs CYP2C19 T98C T CT +/- rs CYP2C19*17 C806T T CC -/- rs CYP2C19*2 G681A A AG +/- rs CYP2C19*2B G276A C GG -/- rs CYP2C19*3 G636A A GG -/- rs CYP2C19*4 A5001G G AA -/- rs CYP2C19*5 C1297T T CC -/- rs CYP2C19*6 G395A A GG -/- rs CYP2C19*7 T24294A A TT -/- rs CYP2C19*8 T358C C TT -/- rs CYP2C19*9 G17784A A GG -/- rs CYP2C19_80161G>A(V331I) A GG -/- V331I rs CYP2C A>G G AA -/- rs CYP2C9 A6326C C AA -/- Page 1/44
2 Liver Detox - Phase I (Figure 1) rs CYP2C9 C334T T CC -/- rs CYP2C9 G2337T T GG -/- rs CYP2C9 G9806A A AG +/- rs CYP2C9 T1188C C CT +/- rs CYP2C9 T2674C T CC -/- rs CYP2C9* C>T T CC -/- rs CYP2C9* C>T T CC -/- rs CYP2C9*2 430C>T T CC -/- rs CYP2C9*3 1075A>C C AA -/- rs CYP2C9*6 818delA D II -/- rs CYP2C9*8 449G>A A GG -/- rs CYP2C9*9 752A>G G AA -/- rs CYP2D6 A1775G T CT +/- rs CYP2D6 C186G C CG +/- rs16947 CYP2D6 C2850T A AG +/- rs CYP2D6 C336T A GG -/- rs CYP2D6 G1659A T CC -/- rs CYP2D6 G2908A T CC -/- rs CYP2D6 G7754A T CC -/- rs CYP2D6 T100C T GG -/- rs CYP2D6 T130G C AC +/- rs CYP2D6 V287M T CC -/- rs CYP2D6* G>A A CC -/- rs CYP2D6*17 T107I A GG -/- rs CYP2D6*2 S486T C CG +/- rs CYP2D6*4 1846G>A T CC -/- rs CYP2D6* G>A T CC -/- rs CYP2D6*7 2935A>C G TT -/- rs CYP2E1 G301A A AG +/- rs CYP2E1 G3378C C GG -/- rs CYP2E1 G625A A GG -/- rs CYP2E1 T766C T CT +/- rs CYP2E1 T8845C C TT -/- rs CYP2E1*1B G9896C G CG +/- rs CYP2E1*3 V389I A GG -/- rs CYP2E1*4 A4768G A GG -/- rs CYP2E1*7_-352A>G A352G G AA -/- rs CYP2E1*7_-71G>T G71T T GT +/- rs CYP2E1_-1055C>T G1055T T CC -/- rs CYP2E1_10463T>C(F421F) T CT +/- F421F rs CYP3A4 C202T A AG +/- rs CYP3A4 T258C G AG +/- rs CYP3A4*16 T185S G GG +/+ Page 2/44
3 Liver Detox - Phase I (Figure 1) rs CYP3A4*18 L293P G AA -/- rs CYP3A4*1B A392G C TT -/- rs CYP3A4*2 S222P G AA -/- rs CYP3A4*3 M445T G AA -/- rs CYP3A4*4 I118V C TT -/- rs CYP3A4*5 P218R C GG -/- rs CYP3A4*_11460A>G(K96E) C TT -/- K96E rs CYP3A5*2 C2899A T GG -/- rs CYP3A5*3 G237A A CT -/- rs CYP3A5*6 G624A T CC -/- rs CYP3A5*9 G1009A T CC -/- rs HFE 193A>T T AA -/- rs662 PON1 Q192R C CT +/- rs SOD3 489 C>T T CT +/- Page 3/44
4 Liver Detox - Phase II (Figure 1) rs ABP1/DAO C1933G G CG +/- rs ABP1/DAO C47T T CC -/- rs ACAT1 G22670A A AG +/- rs4343 ACE G2328A G AA -/- rs ADA A534G G TT -/- rs ADA C10783T A GG -/- rs ADA G22021A C CT +/- rs ADA G22A T CC -/- rs4961 ADD1 G460W T GT +/- rs ADH1B A14973G C TT -/- rs ADH1B A178T A TT -/- rs ADH1B A19107G C CT +/- rs ADH1B A396C A GG -/- rs ADH1B A5998G C TT -/- rs ADH1B A7571G C TT -/- rs ADH1B A8575G C CT +/- rs ADH1B C8282A T GG -/- rs ADH1B C9160T A AG +/- rs ADK G509567T T GG -/- rs699 AGT M235T/C4072T G GG +/+ rs AHCY-01 G14905A C TT -/- rs AMT T5998G C CC +/+ rs5128 APOC3 3u386 G CG +/- rs4520 APOC3 G34G T TT +/+ rs BHMT A7961G G AA -/- rs BHMT R239Q A AA +/+ rs BHMT-02 C13813T T CC -/- rs BHMT-08 C6457T T CC -/- rs BMP2 C282Y G AA -/- rs CAT A12175G G AA -/- rs CAT C14185T T CC -/- rs CAT C21068T T TT +/+ rs CAT T5070C C CC +/+ rs COMT/TXNRD2 A4251G C TT -/- rs COMT/TXNRD2 C4622T T CC -/- rs COMT/TXNRD2 T4239C G AA -/- rs DAO A14747C C AC +/- rs DAO A24464G G AG +/- rs DAO G8864A A AG +/- rs DAO/ABP1 C995T T CC -/- rs DHFR A16352G C TT -/- rs DHFR A20965G C TT -/- rs DHFR C19483A T GG -/- rs DHFR/MSH T-473A A AG +/- Page 4/44
5 Liver Detox - Phase II (Figure 1) rs DISC1 C14853T C TT -/- rs DISC1 R264Q A GG -/- rs DMGDH G67591T C AA -/- rs DMGDH T835C A AG +/- rs DTNBP1 C11202T A AG +/- rs DTNBP1 T14623G C AC +/- rs FOLR1 G-20A A GG -/- rs FOLR2 G-1316A A AG +/- rs FOLR3 A3771G G AA -/- rs FUT2 A12190G G AA -/- rs FUT2 A12404T T AT +/- rs FUT2 C12376T T TT +/+ rs FUT2 G12447A A GG -/- rs FUT2 G12758A A GG -/- rs G6PD A*357G C TT -/- rs G6PD C1311T A GG -/- rs G6PD G1478A T CC -/- rs G6PD G6PD-A(+) C TT -/- rs G6PD/IKBKG G6PD-A(-) T CC -/- rs G6PD/IKBKG G6PD-Mediterran A GG -/- rs GAD1 C10180T C TT -/- rs GAD1 C14541T T CT +/- rs GAD1 C2627A A AC +/- rs GAD1 C34281T T CT +/- rs GAD1 G25509C C CG +/- rs GAD1 G39901A A GG -/- rs GAD1 G3992T T GG -/- rs GAD1 G5276A A GG -/- rs GAD1 T21922C C TT -/- rs GAD1 T30473C C CT +/- rs GAMT C9110T A GG -/- rs GAMT G7497A T CC -/- rs GART A9979G T CC -/- rs GGH C15472T A GG -/- rs GGH C23421T A AG +/- rs GGH C6699T A AG +/- rs GGH G13894A T CC -/- rs GGH G174A T CC -/- rs GGH G91A T CC -/- rs GGT1 C17146T T CC -/- rs GGT1 T17549C T CT +/- rs GSR A43851G C CC +/+ rs GSS A18836C T TT +/+ rs GSS A5997G T CC -/- Page 5/44
6 Liver Detox - Phase II (Figure 1) rs GSS C373T A GG -/- rs GSS G11705T A AA +/+ rs GSTM1 7730C>T T CC -/- rs7483 GSTM3 V224I T CT +/- rs GSTP1 A114V T CC -/- rs1695 GSTP1 I105V G AG +/- rs HDC A1932C G GT +/- rs HDC T10086C G AG +/- rs HDC T1657C G AA -/- rs HFE 6382T>G G GG +/+ rs HFE 8828T>C C TT -/- rs HFE C282Y A GG -/- rs HFE H63D G CC -/- rs HNMT A47507G G AA -/- rs HNMT T939C G AA -/- rs HRH1 T-17C T CC -/- rs HRH4 A617G G AA -/- rs HRH4 C413T T CC -/- rs HRH4 G*2144A A GG -/- rs HRH4 T C C TT -/- rs HTR2A T64185C G AG +/- rs IDO1 G344A A GG -/- rs MAT1A C1131T A GG -/- rs MAT1A C15656T A GG -/- rs MAT1A T*1297C G GG +/+ rs MAT2B A G G AG +/- rs MMAB G16110A C CC +/+ rs MMAB/MVK A-818G A AA +/+ rs MPO A15067C G TT -/- rs MPO C7900T A GG -/- rs MTHFD1 C105T C CT +/- rs MTHFD1 G1958A A GG -/- rs MTHFD1L A33780G A GG -/- rs MTHFD1L G25264A A GG -/- rs MTHFD1L G71171A A GG -/- rs MTHFD1L T31397C C CT +/- rs MTHFD2 C8503T C CT +/- rs MTHFS - ST20 MTHFS C CT +/- G39646A rs MTHFS - ST20 MTHFS T CC -/- G56057A rs NAT1 R187Q A GG -/- rs NAT2 C282T T TT +/+ rs NAT2 C481T T CC -/- Page 6/44
7 Liver Detox - Phase II (Figure 1) rs NAT2 G191A A GG -/- rs NAT2 G286E A AA +/+ rs NAT2 I114T C TT -/- rs1208 NAT2 K268R G AA -/- rs NAT2 R197Q A GG -/- rs NAT2 R64W T CC -/- rs10517 NQO1 C494+ A GG -/- rs NQO1 C609T A AA +/+ rs NQO1 G13070C C GG -/- rs NQO1 G13161A T CC -/- rs NQO1 G13528A T CC -/- rs NQO1 T6314C A GG -/- rs NQO1 T7706C G GG +/+ rs NRG1 C3314T T CT +/- rs SLC6A2 A40223G G AG +/- rs5568 SLC6A2 A45583C C AC +/- rs SLC6A2 C10565T T CC -/- rs36020 SLC6A2 C28547T T CC -/- rs SLC6A2 C35917A A CC -/- rs SLC6A2 C41517T T CC -/- rs SLC6A2 C45295T T CT +/- rs36009 SLC6A2 C48079T T CC -/- rs SLC6A2 C51371T C TT -/- rs SLC6A2 C5884T C CT +/- rs SLC6A2 G13486A G AG +/- rs40147 SLC6A2 G32299A A AA +/+ rs SLC6A2 G47034T T GT +/- rs SLC6A2 T32009C T CC -/- rs5558 SLC6A2 T49018G G TT -/- rs6347 SLC6A3 A39132G C TT -/- rs SLC6A3 A8023G C TT -/- rs SLC6A3 C17719T T GG -/- rs SLC6A3 C51747T A GG -/- rs6350 SLC6A3 C7345T A GG -/- rs27048 SLC6A3 G37899A C CC +/+ rs SLC6A3 G45996T T CC -/- rs SLC6A3 G48964A T CT +/- rs40184 SLC6A3 G55467A T TT +/+ rs27072 SLC6A3 G56022A C CC +/+ rs SLC6A3 T12190G A AA +/+ rs SLC6A3 T26639C A AA +/+ rs SLC6A3 T55729C G AG +/- rs SPR 7413A>G A GG -/- rs SULT1A1 C*85G A GG -/- Page 7/44
8 Liver Detox - Phase II (Figure 1) rs SULT1C3 A G A GG -/- rs SULT1C3 C T T CC -/- rs SULT1C3 G535A A AG +/- rs SULT1C3 M194T T CT +/- rs SULT2A1 A20117G T CC -/- rs SULT2A1 C90C A GG -/- rs SULT2A1 G17136A T CC -/- rs SULT2A1 G781A T CC -/- rs SULT2A1 G9598T C AA -/- rs SULT2A1 G9696A T CC -/- rs UGT1A1 C175181T T CC -/- rs UGT1A1 C179920T T CC -/- rs UGT1A1 G179250T T GG -/- rs UGT1A1 G182349A A GG -/- rs UGT1A1 G211A A GG -/- rs UGT1A1 G354A G AA -/- rs UGT1A1 L175G A TT -/- rs UGT2A2, UGT2A1 G308R T CC -/- rs VDR Bsm VDR:BsmI T CC -/- Page 8/44
9 Yeast/Alcohol Metabolism (Figure 2) rs ADH1B A14973G C TT -/- rs ADH1B A178T A TT -/- rs ADH1B A19107G C CT +/- rs ADH1B A396C A GG -/- rs ADH1B A5998G C TT -/- rs ADH1B A7571G C TT -/- rs ADH1B A8575G C CT +/- rs ADH1B C8282A T GG -/- rs ADH1B C9160T A AG +/- rs ALDH2 C23443T T CC -/- rs ALDH2 C36438A A CC -/- rs ALDH2 C45068T T CC -/- rs671 ALDH2 G1369A A GG -/- rs ALDH2 T12488C T CT +/- rs441 ALDH2 T29504C G TT -/- rs ALDH2 T35023C T CC -/- rs ALDH3A2 A1157G G AA -/- rs ALDH3A2 C13996T T CC -/- rs ALDH3A2 G641A A GG -/- Page 9/44
10 Methylation & Methionine/Homocysteine Pathways (Figure 3) rs AHCY-01 G14905A C TT -/- rs ALDH3A2 A1157G G AA -/- rs ALDH3A2 C13996T T CC -/- rs ALDH3A2 G641A A GG -/- rs BHMT A7961G G AA -/- rs BHMT R239Q A AA +/+ rs BHMT-02 C13813T T CC -/- rs BHMT-08 C6457T T CC -/- rs CBS A13637G T CC -/- rs CBS A360A A AA +/+ rs CBS C*351T A AA +/+ rs CBS C19150T A GG -/- rs CBS C699T A GG -/- rs12613 CBS G*299A T CC -/- rs CBS T*330C G GG +/+ rs CTH A11886G A AA +/+ rs CTH A32114G G AA -/- rs CTH G25229T T GG -/- rs CTH G6010A A GG -/- rs CTH S4031I T TT +/+ rs CTH T16147C C TT -/- rs CTH T8763C T TT +/+ rs DHFR A16352G C TT -/- rs DHFR A20965G C TT -/- rs DHFR C19483A T GG -/- rs DHFR/MSH T-473A A AG +/- rs DMGDH G67591T C AA -/- rs DMGDH T835C A AG +/- rs FOLR1 G-20A A GG -/- rs FOLR2 G-1316A A AG +/- rs FOLR3 A3771G G AA -/- rs GAMT C9110T A GG -/- rs GAMT G7497A T CC -/- rs GSS A18836C T TT +/+ rs GSS A5997G T CC -/- rs GSS C373T A GG -/- rs GSS G11705T A AA +/+ rs MAT1A C1131T A GG -/- rs MAT1A C15656T A GG -/- rs MAT1A T*1297C G GG +/+ rs MAT2B A G G AG +/- rs MTHFD1 C105T C CT +/- rs MTHFD1 G1958A A GG -/- rs MTHFD1L A33780G A GG -/- Page 10/44
11 Methylation & Methionine/Homocysteine Pathways (Figure 3) rs MTHFD1L G25264A A GG -/- rs MTHFD1L G71171A A GG -/- rs MTHFD1L T31397C C CT +/- rs MTHFD2 C8503T C CT +/- rs MTHFR 03 P39P A AG +/- rs MTHFR A*372C T GG -/- rs MTHFR A1298C G TT -/- rs MTHFR A1572G G AG +/- rs MTHFR A4117C T CC -/- rs MTHFR C-137T T CC -/- rs MTHFR C10318T A GG -/- rs MTHFR C24909T G AA -/- rs MTHFR C677T A GG -/- rs MTHFR G1793A (R594Q) T CC -/- rs MTHFR G18861A T CC -/- rs MTHFS - ST20 MTHFS C CT +/- G39646A rs MTHFS - ST20 MTHFS T CC -/- G56057A rs MTR A*153G G AA -/- rs MTR A2756G G AG +/- rs MTR A50417C A AC +/- rs MTR A68550G G AG +/- rs MTR A92580G G AG +/- rs MTR C62048T T CC -/- rs MTR G106853T G GT +/- rs MTR G34783A A GG -/- rs MTR G35489C G GG +/+ rs MTR G74984T G GT +/- rs MTR G94982A G AG +/- rs MTR G95096T T GT +/- rs MTR T9195C T CT +/- rs MTRR -11 A664A A AG +/- rs MTRR A22893G G AG +/- rs MTRR A66G G AG +/- rs MTRR C1078G G CC -/- rs MTRR C32295T T CT +/- rs MTRR C524T T CT +/- rs9332 MTRR G*541A A GG -/- rs MTRR G1155A A GG -/- rs MTRR G12099A G AG +/- rs MTRR G15734A A GG -/- rs MTRR K350A G AA -/- rs8659 MTRR T*662A A AT +/- Page 11/44
12 Methylation & Methionine/Homocysteine Pathways (Figure 3) rs MTRR T12072C C CT +/- rs MTRR T16071C T CT +/- rs MUT T24234C G GG +/+ rs NOS1 A57373G C CT +/- rs NOS1 T2202C A GG -/- rs NOS2 C1823T A AG +/- rs NOS2 T32235C A AG +/- rs NOS2 T836165G T GT +/- rs NOS3 A6251T A TT -/- rs NOS3 C19635T A AC +/- rs NOS3 G6797A G AA -/- rs7946 PEMT G634A T CT +/- rs PEMT T A A AT +/- rs PEMT T G T GT +/- rs SULT1A1 C*85G A GG -/- rs SULT1C3 A G A GG -/- rs SULT1C3 C T T CC -/- rs SULT1C3 G535A A AG +/- rs SULT1C3 M194T T CT +/- rs SULT2A1 A20117G T CC -/- rs SULT2A1 C90C A GG -/- rs SULT2A1 G17136A T CC -/- rs SULT2A1 G781A T CC -/- rs SULT2A1 G9598T C AA -/- rs SULT2A1 G9696A T CC -/- rs TCN1 G A G AA -/- rs TCN2 A8700G G AA -/- rs TCN2 C766G G CC -/- Page 12/44
13 Trans-Sulfuration Pathway (Figure 4) rs CBS A13637G T CC -/- rs CBS A360A A AA +/+ rs CBS C*351T A AA +/+ rs CBS C19150T A GG -/- rs CBS C699T A GG -/- rs12613 CBS G*299A T CC -/- rs CBS T*330C G GG +/+ rs CTH A11886G A AA +/+ rs CTH A32114G G AA -/- rs CTH G25229T T GG -/- rs CTH G6010A A GG -/- rs CTH S4031I T TT +/+ rs CTH T16147C C TT -/- rs CTH T8763C T TT +/+ rs GSS A18836C T TT +/+ rs GSS A5997G T CC -/- rs GSS C373T A GG -/- rs GSS G11705T A AA +/+ rs MTHFS - ST20 MTHFS C CT +/- G39646A rs MTHFS - ST20 MTHFS T CC -/- G56057A rs MUT T24234C G GG +/+ rs SULT1A1 C*85G A GG -/- rs SULT1C3 A G A GG -/- rs SULT1C3 C T T CC -/- rs SULT1C3 G535A A AG +/- rs SULT1C3 M194T T CT +/- rs SULT2A1 A20117G T CC -/- rs SULT2A1 C90C A GG -/- rs SULT2A1 G17136A T CC -/- rs SULT2A1 G781A T CC -/- rs SULT2A1 G9598T C AA -/- rs SULT2A1 G9696A T CC -/- rs SUOX C5444T T CC -/- Page 13/44
14 Neurotransmitter Pathway: Serotonin & Dopamine (Figure 5) rs AANAT C10236T T TT +/+ rs ALDH2 C23443T T CC -/- rs ALDH2 C36438A A CC -/- rs ALDH2 C45068T T CC -/- rs671 ALDH2 G1369A A GG -/- rs ALDH2 T12488C T CT +/- rs441 ALDH2 T29504C G TT -/- rs ALDH2 T35023C T CC -/- rs ALDH3A2 A1157G G AA -/- rs ALDH3A2 C13996T T CC -/- rs ALDH3A2 G641A A GG -/- rs ANK3 C666301A T GG -/- rs ANK3 G318473A T CC -/- rs ANK3 G658454A T CC -/- rs ANK3 T197902C G AA -/- rs ANK3 T C T CC -/- rs ANKK1 E713K A AA +/+ rs ANKK1 G318R A GG -/- rs CACNA1C A G G AA -/- rs CACNA1C C271442T T CC -/- rs CACNA1C G115699A A GG -/- rs CACNA1C T709021C T CC -/- rs COMT -61 P199P A AG +/- rs COMT A 26166G G AG +/- rs6269 COMT A-1324G G AG +/- rs COMT A309G T CT +/- rs COMT A7406G A AG +/- rs COMT C27870T G CT -/- rs COMT C28914T C CT +/- rs COMT C30196T C TT -/- rs COMT C31430T T CC -/- rs COMT G*522A G AG +/- rs COMT G28299A A GG -/- rs4633 COMT H62H T CT +/- rs COMT T13376G G GT +/- rs COMT T24075C C CT +/- rs COMT T26501G T GT +/- rs4680 COMT V158M A AG +/- rs DBH T CC -/- rs77905 DBH A1410G A GG -/- rs DBH A486G A AG +/- rs DBH A8757G G AG +/- rs DBH C12599T T CT +/- rs DBH C12828T C CT +/- Page 14/44
15 Neurotransmitter Pathway: Serotonin & Dopamine (Figure 5) rs DBH C18813T C CC +/+ rs5324 DBH G12174A A GG -/- rs DBH G15032A G AA -/- rs4531 DBH G952T T GG -/- rs DBH T13150C C CT +/- rs DBH T15791C C CT +/- rs DBH T16031C T CC -/- rs DBH T2145C G AG +/- rs DBH T7335C C CT +/- rs DBH T8114C C TT -/- rs DBH T9160C C CT +/- rs DDC A14870G T CC -/- rs DDC A19551G C TT -/- rs6263 DDC A415G C TT -/- rs DDC A85104G T TT +/+ rs DDC C166017G C CC +/+ rs DDC C186233T C CC +/+ rs DDC G108706C G CG +/- rs DDC G1385A T CC -/- rs DDC G15443T A AA +/+ rs DDC G196757C C GG -/- rs DDC G219133T G TT -/- rs DDC T155196C C CC +/+ rs DDC T94092G C AA -/- rs DHFR A16352G C TT -/- rs DHFR A20965G C TT -/- rs DHFR C19483A T GG -/- rs DHFR/MSH T-473A A AG +/- rs686 DRD1 C7464T A AG +/- rs5326 DRD1 G5968A T CT +/- rs4532 DRD1 G6014A T CT +/- rs DRD1 T5262C G AG +/- rs DRD2 A32594G C CT +/- rs DRD2 A33029G T CT +/- rs DRD2 A37613G C CT +/- rs DRD2 A4651G C TT -/- rs DRD2 A53817G C CC +/+ rs DRD2 A61820G T CC -/- rs DRD2 A64124G T CC -/- rs DRD2 A9611G C CT +/- rs DRD2 C19470T A AG +/- rs DRD2 C31550T G AG +/- rs DRD2 C33935T A GG -/- rs DRD2 C36639T A AG +/- Page 15/44
16 Neurotransmitter Pathway: Serotonin & Dopamine (Figure 5) rs DRD2 C41383T A GG -/- rs DRD2 C71572T G AA -/- rs DRD2 C72519G G CC -/- rs6277 DRD2 C957T G GG +/+ rs DRD2 G26528A C CT +/- rs DRD2 G41133A T CC -/- rs DRD2 G44237A C TT -/- rs DRD2 G52663A T TT +/+ rs DRD2 G54383A T TT +/+ rs DRD2 G54716A T TT +/+ rs DRD2 G65466T C AA -/- rs DRD2 G67314T A AA +/+ rs DRD2 T21228G A AC +/- rs DRD2 T4047C G AA -/- rs DRD2 T55093G C AA -/- rs DRD2 T64501C G AA -/- rs DRD3 C26625T G AG +/- rs DRD3 C40013T A GG -/- rs DRD3 G17248T A AC +/- rs6280 DRD3 G25A T CC -/- rs DRD3 G50169T C AA -/- rs DRD3 T14368C G AG +/- rs DRD3 T21277C A AA +/+ rs DRD3 T27841C A GG -/- rs DRD3 T29528C A GG -/- rs DRD3 T32822C A GG -/- rs DRD3 T43727C G AA -/- rs DRD4 C4710T T CC -/- rs DRD4 C8887A A AA +/+ rs DRD4 T4095C C TT -/- rs DRD4 T581G G TT -/- rs GCH1 T GG -/- rs GCH1 A14340G C CT +/- rs GCH1 A14404T A AT +/- rs GCH1 A30528G C CT +/- rs GCH1 A53980G C CC +/+ rs GCH1 C12707T A AG +/- rs GCH1 C15878T A AG +/- rs GCH1 C T T CT +/- rs GCH1 C37668A T GT +/- rs GCH1 G19512A T CC -/- rs GCH1 G26425A T CT +/- rs GCH1 G C C CC +/+ rs GCH1 G62974A T TT +/+ Page 16/44
17 Neurotransmitter Pathway: Serotonin & Dopamine (Figure 5) rs MAOA A16535C A AC +/- rs MAOA A85020G A AG +/- rs MAOA C42794T C CT +/- rs MAOA G3638A G AG +/- rs6323 MAOA R297R/G492T/T941G T GT +/- rs MAOA T1011C/1460C C CT +/- rs MAOA T89113C C CT +/- rs MAOB A118723G C TT -/- rs NOS1 A57373G C CT +/- rs NOS1 T2202C A GG -/- rs NOS2 C1823T A AG +/- rs NOS2 T32235C A AG +/- rs NOS2 T836165G T GT +/- rs NOS3 A6251T A TT -/- rs NOS3 C19635T A AC +/- rs NOS3 G6797A G AA -/- rs PAH A27743C C TT -/- rs PAH A55562G C CT +/- rs PAH C1222T A GG -/- rs PAH C35625G G GG +/+ rs PAH C45188T A GG -/- rs PAH C5594T A AG +/- rs PAH C81837T A GG -/- rs PAH G*187A T CC -/- rs PAH G1155C G CG +/- rs PAH G735A T CT +/- rs PAH G782A A CC -/- rs PAH T17864C G AG +/- rs PAH T31338A T AT +/- rs PAH T32409C A GG -/- rs7946 PEMT G634A T CT +/- rs PEMT T A A AT +/- rs PEMT T G T GT +/- rs5638 PNMT A456G G AA -/- rs PNMT G-184A A GG -/- rs SLC6A2 A40223G G AG +/- rs5568 SLC6A2 A45583C C AC +/- rs SLC6A2 C10565T T CC -/- rs36020 SLC6A2 C28547T T CC -/- rs SLC6A2 C35917A A CC -/- rs SLC6A2 C41517T T CC -/- rs SLC6A2 C45295T T CT +/- rs36009 SLC6A2 C48079T T CC -/- rs SLC6A2 C51371T C TT -/- Page 17/44
18 Neurotransmitter Pathway: Serotonin & Dopamine (Figure 5) rs SLC6A2 C5884T C CT +/- rs SLC6A2 G13486A G AG +/- rs40147 SLC6A2 G32299A A AA +/+ rs SLC6A2 G47034T T GT +/- rs SLC6A2 T32009C T CC -/- rs5558 SLC6A2 T49018G G TT -/- rs6347 SLC6A3 A39132G C TT -/- rs SLC6A3 A8023G C TT -/- rs SLC6A3 C17719T T GG -/- rs SLC6A3 C51747T A GG -/- rs6350 SLC6A3 C7345T A GG -/- rs27048 SLC6A3 G37899A C CC +/+ rs SLC6A3 G45996T T CC -/- rs SLC6A3 G48964A T CT +/- rs40184 SLC6A3 G55467A T TT +/+ rs27072 SLC6A3 G56022A C CC +/+ rs SLC6A3 T12190G A AA +/+ rs SLC6A3 T26639C A AA +/+ rs SLC6A3 T55729C G AG +/- rs TH A733C G TT -/- rs TH G1010A//R337H T CC -/- rs TH T1090C C AA -/- rs6356 TH V112M T TT +/+ Page 18/44
19 Neurotransmitter Pathway: Glutamate & GABA (Figure 6) rs GAD1 C10180T C TT -/- rs GAD1 C14541T T CT +/- rs GAD1 C2627A A AC +/- rs GAD1 C34281T T CT +/- rs GAD1 G25509C C CG +/- rs GAD1 G39901A A GG -/- rs GAD1 G3992T T GG -/- rs GAD1 G5276A A GG -/- rs GAD1 T21922C C TT -/- rs GAD1 T30473C C CT +/- Page 19/44
20 COMT Activity (Figure 7) rs ALDH2 C23443T T CC -/- rs ALDH2 C36438A A CC -/- rs ALDH2 C45068T T CC -/- rs671 ALDH2 G1369A A GG -/- rs ALDH2 T12488C T CT +/- rs441 ALDH2 T29504C G TT -/- rs ALDH2 T35023C T CC -/- rs ALDH3A2 A1157G G AA -/- rs ALDH3A2 C13996T T CC -/- rs ALDH3A2 G641A A GG -/- rs ANK3 C666301A T GG -/- rs ANK3 G318473A T CC -/- rs ANK3 G658454A T CC -/- rs ANK3 T197902C G AA -/- rs ANK3 T C T CC -/- rs ANKK1 E713K A AA +/+ rs ANKK1 G318R A GG -/- rs CACNA1C A G G AA -/- rs CACNA1C C271442T T CC -/- rs CACNA1C G115699A A GG -/- rs CACNA1C T709021C T CC -/- rs COMT -61 P199P A AG +/- rs COMT A 26166G G AG +/- rs6269 COMT A-1324G G AG +/- rs COMT A309G T CT +/- rs COMT A7406G A AG +/- rs COMT C27870T G CT -/- rs COMT C28914T C CT +/- rs COMT C30196T C TT -/- rs COMT C31430T T CC -/- rs COMT G*522A G AG +/- rs COMT G28299A A GG -/- rs4633 COMT H62H T CT +/- rs COMT T13376G G GT +/- rs COMT T24075C C CT +/- rs COMT T26501G T GT +/- rs4680 COMT V158M A AG +/- rs CYP1A1*2C A4889G C CT +/- rs CYP1A1*4 C2453A T GG -/- rs CYP1B1 L432V C GG -/- rs CYP1B1 N453S T TT +/+ rs10012 CYP1B1 R48G G CG +/- rs DBH T CC -/- rs77905 DBH A1410G A GG -/- Page 20/44
21 COMT Activity (Figure 7) rs DBH A486G A AG +/- rs DBH A8757G G AG +/- rs DBH C12599T T CT +/- rs DBH C12828T C CT +/- rs DBH C18813T C CC +/+ rs5324 DBH G12174A A GG -/- rs DBH G15032A G AA -/- rs4531 DBH G952T T GG -/- rs DBH T13150C C CT +/- rs DBH T15791C C CT +/- rs DBH T16031C T CC -/- rs DBH T2145C G AG +/- rs DBH T7335C C CT +/- rs DBH T8114C C TT -/- rs DBH T9160C C CT +/- rs686 DRD1 C7464T A AG +/- rs5326 DRD1 G5968A T CT +/- rs4532 DRD1 G6014A T CT +/- rs DRD1 T5262C G AG +/- rs DRD2 A32594G C CT +/- rs DRD2 A33029G T CT +/- rs DRD2 A37613G C CT +/- rs DRD2 A4651G C TT -/- rs DRD2 A53817G C CC +/+ rs DRD2 A61820G T CC -/- rs DRD2 A64124G T CC -/- rs DRD2 A9611G C CT +/- rs DRD2 C19470T A AG +/- rs DRD2 C31550T G AG +/- rs DRD2 C33935T A GG -/- rs DRD2 C36639T A AG +/- rs DRD2 C41383T A GG -/- rs DRD2 C71572T G AA -/- rs DRD2 C72519G G CC -/- rs6277 DRD2 C957T G GG +/+ rs DRD2 G26528A C CT +/- rs DRD2 G41133A T CC -/- rs DRD2 G44237A C TT -/- rs DRD2 G52663A T TT +/+ rs DRD2 G54383A T TT +/+ rs DRD2 G54716A T TT +/+ rs DRD2 G65466T C AA -/- rs DRD2 G67314T A AA +/+ rs DRD2 T21228G A AC +/- Page 21/44
22 COMT Activity (Figure 7) rs DRD2 T4047C G AA -/- rs DRD2 T55093G C AA -/- rs DRD2 T64501C G AA -/- rs DRD3 C26625T G AG +/- rs DRD3 C40013T A GG -/- rs DRD3 G17248T A AC +/- rs6280 DRD3 G25A T CC -/- rs DRD3 G50169T C AA -/- rs DRD3 T14368C G AG +/- rs DRD3 T21277C A AA +/+ rs DRD3 T27841C A GG -/- rs DRD3 T29528C A GG -/- rs DRD3 T32822C A GG -/- rs DRD3 T43727C G AA -/- rs DRD4 C4710T T CC -/- rs DRD4 C8887A A AA +/+ rs DRD4 T4095C C TT -/- rs DRD4 T581G G TT -/- rs MAOA A16535C A AC +/- rs MAOA A85020G A AG +/- rs MAOA C42794T C CT +/- rs MAOA G3638A G AG +/- rs6323 MAOA R297R/G492T/T941G T GT +/- rs MAOA T1011C/1460C C CT +/- rs MAOA T89113C C CT +/- rs MAOB A118723G C TT -/- rs PAH A27743C C TT -/- rs PAH A55562G C CT +/- rs PAH C1222T A GG -/- rs PAH C35625G G GG +/+ rs PAH C45188T A GG -/- rs PAH C5594T A AG +/- rs PAH C81837T A GG -/- rs PAH G*187A T CC -/- rs PAH G1155C G CG +/- rs PAH G735A T CT +/- rs PAH G782A A CC -/- rs PAH T17864C G AG +/- rs PAH T31338A T AT +/- rs PAH T32409C A GG -/- rs5638 PNMT A456G G AA -/- rs PNMT G-184A A GG -/- rs TH A733C G TT -/- rs TH G1010A//R337H T CC -/- Page 22/44
23 COMT Activity (Figure 7) rs TH T1090C C AA -/- rs6356 TH V112M T TT +/+ Page 23/44
24 Mitochondrial Function (Figure 8) rs ALDH2 C23443T T CC -/- rs ALDH2 C36438A A CC -/- rs ALDH2 C45068T T CC -/- rs671 ALDH2 G1369A A GG -/- rs ALDH2 T12488C T CT +/- rs441 ALDH2 T29504C G TT -/- rs ALDH2 T35023C T CC -/- rs ALDH3A2 A1157G G AA -/- rs ALDH3A2 C13996T T CC -/- rs ALDH3A2 G641A A GG -/- rs ATP5c1 T CC -/- rs ATP5g3 C TT -/- rs COX5A G AA -/- rs COX6C C TT -/- rs DMGDH G67591T C AA -/- rs DMGDH T835C A AG +/- rs GAMT C9110T A GG -/- rs GAMT G7497A T CC -/- rs GCH1 T GG -/- rs GCH1 A14340G C CT +/- rs GCH1 A14404T A AT +/- rs GCH1 A30528G C CT +/- rs GCH1 A53980G C CC +/+ rs GCH1 C12707T A AG +/- rs GCH1 C15878T A AG +/- rs GCH1 C T T CT +/- rs GCH1 C37668A T GT +/- rs GCH1 G19512A T CC -/- rs GCH1 G26425A T CT +/- rs GCH1 G C C CC +/+ rs GCH1 G62974A T TT +/+ rs GSS A18836C T TT +/+ rs GSS A5997G T CC -/- rs GSS C373T A GG -/- rs GSS G11705T A AA +/+ rs MAT1A C1131T A GG -/- rs MAT1A C15656T A GG -/- rs MAT1A T*1297C G GG +/+ rs MAT2B A G G AG +/- rs MTHFD1 C105T C CT +/- rs MTHFD1 G1958A A GG -/- rs MTHFD1L A33780G A GG -/- rs MTHFD1L G25264A A GG -/- rs MTHFD1L G71171A A GG -/- Page 24/44
25 Mitochondrial Function (Figure 8) rs MTHFD1L T31397C C CT +/- rs MTHFD2 C8503T C CT +/- rs MTRR -11 A664A A AG +/- rs MTRR A22893G G AG +/- rs MTRR A66G G AG +/- rs MTRR C1078G G CC -/- rs MTRR C32295T T CT +/- rs MTRR C524T T CT +/- rs9332 MTRR G*541A A GG -/- rs MTRR G1155A A GG -/- rs MTRR G12099A G AG +/- rs MTRR G15734A A GG -/- rs MTRR K350A G AA -/- rs8659 MTRR T*662A A AT +/- rs MTRR T12072C C CT +/- rs MTRR T16071C T CT +/- rs MUT T24234C G GG +/+ rs NDUFS3 A GG -/- rs NDUFS7 T CC -/- rs NDUFS7 A GG -/- rs NDUFS7 G AA -/- rs NDUFS8 T CC -/- rs NDUFS8 C TT -/- rs NDUFS8 A GG -/- rs NOS1 A57373G C CT +/- rs NOS1 T2202C A GG -/- rs NOS2 C1823T A AG +/- rs NOS2 T32235C A AG +/- rs NOS2 T836165G T GT +/- rs NOS3 A6251T A TT -/- rs NOS3 C19635T A AC +/- rs NOS3 G6797A G AA -/- rs7946 PEMT G634A T CT +/- rs PEMT T A A AT +/- rs PEMT T G T GT +/- rs SOD G>T A CC -/- rs4880 SOD2 A16V G AA -/- rs UQCRC2 T GG -/- rs4850 UQCRC2 A GG -/- Page 25/44
26 Alzheimers/Cardio/Lipid rs A2M A T T AA -/- rs ABCA2 T15891C A GG -/- rs ABCA7 T G G GT +/- rs ADAM12 G63103C C CG +/- rs APBB2 G C C CC +/+ rs APOE A178G G AA -/- rs7412 APOE APOE epsilon 2 T CT +/- rs APOE ApoE epsilon 4 C TT -/- rs APOE C8002T T CC -/- rs APOE G455A A GG -/- rs APOE IVS1+69 G CG +/- rs APP Ala655Thr T CC -/- rs APP Ala674Gly G GG +/+ rs APP Ala695Thr T CC -/- rs APP Glu647Asp C CC +/+ rs APP Ile698Val C TT -/- rs APP Thr696Ala C TT -/- rs APP Thr696Ile T GG -/- rs APP Val586Gly C AA -/- rs APP Val697Met T CC -/- rs BCHE CHE*539T T CC -/- rs BDNF T64089C A GG -/- rs6265 BDNF V81M T TT +/+ rs CETP C4402A C AC +/- rs5882 CETP I405V A AA +/+ rs CHAT Asp7Asn A GG -/- rs CLU A58V T CC -/- rs CR1 A27577G A GG -/- rs17571 CTSD A58V A AG +/- rs CYP4V2 Q259K C AC +/- rs EIF2AK2 C12900T G AG +/- rs F A5397C G GG +/+ rs F11 C25264T T CT +/- i F2 (Prothrombin 20210A) A GG -/- Prothrombin 20210A rs5896 F2 C494T T TT +/+ rs F A10547G C TT -/- rs6025 F5 Factor V Leiden FVL T CC -/- rs6046 F7 A353G Arg329Gln A GG -/- rs6048 F9 G580A A25386G G AA -/- rs GAB2 G42719T A AC +/- rs GP6 Pro219Ser G AA -/- rs HFE C282Y A GG -/- rs HFE H63D G CC -/- Page 26/44
27 Alzheimers/Cardio/Lipid i HFE S65C T AA -/- rs9898 HRG Pro204Ser T CT +/- rs IDE G91606A T CC -/- rs IL6 A6262G G AG +/- rs5918 ITGB3 P1A2/T196C C TT -/- rs8702 KLC1 C.*396G G GG +/+ rs KNG I598T GP IIIa HPA-1 T TT +/+ rs688 LDLR Asn464 T CC -/- rs LRP6 Cys1270 A GG -/- rs LRP6 T154522C A GG -/- rs LRP6 V1062I T TT +/+ rs MAPT A52950A A AA +/+ rs MTHFD1L G25264A A GG -/- rs NR1I2 C6709A C AA -/- rs OLR1 T17500A T AA -/- rs PCSK9 R46L T GG -/- rs PSEN1 Ala242Glu A CC -/- rs PSEN1 Ala422Pro C GG -/- rs PSEN1 Ala75Val T CC -/- rs PSEN1 Arg265His A GG -/- rs PSEN1 Glu314Gly G AA -/- rs PSEN1 Gly179Val T GG -/- rs PSEN1 His159Arg G AA -/- rs PSEN1 Leu170Met A CC -/- rs PSEN1 Leu246Ser C TT -/- rs PSEN1 Leu282Val G CC -/- rs PSEN1 Leu81Pro C TT -/- rs PSEN1 Met135Val G AA -/- rs PSEN1 Pro263Ser T CC -/- rs PSEN1 Ser166Phe T CC -/- rs PSEN1 T66540C C TT -/- rs PSEN1 Tyr252Ser C AA -/- rs PSEN1 Val85Leu T GG -/- rs PSEN2 Ala85Val T CC -/- rs PSEN2 Asp438Ala C AA -/- rs PSEN2 Met174Val G AA -/- rs PSEN2 Met239Ile A GG -/- rs PSEN2 Met239Val G AA -/- rs PSEN2 Ser130Leu T CC -/- rs PSEN2 Thr122Pro C AA -/- rs PSEN2 Thr429Met T CC -/- rs6859 PVRL2 A37642G A AG +/- rs RNF219 T C C TT -/- rs SERPINC1 G5301A T TT +/+ Page 27/44
28 Alzheimers/Cardio/Lipid rs SORL1 A123560G A GG -/- rs SORL1 C163447T T CT +/- rs SORL1 C164978A C AC +/- rs SORL1 G105680A A GG -/- rs SORL1 G106922A A GG -/- rs SORL1 G108082A A GG -/- rs SORL1 G130294A A GG -/- rs SORL1 G146128A A GG -/- rs SORL1 T C C TT -/- rs TF C34378T T CC -/- rs1937 TFAM Ser12Thr C GG -/- rs THBD A7681G C CT +/- rs TLR4 D299G G AA -/- rs TOMM40 A G G AA -/- rs TOMM40 G A G AG +/- rs TTR Gly26Ser A GG -/- rs WWC1 G179644A A AG +/- Page 28/44
29 IgE rs CD14 C CT +/- rs DARC C TT -/- rs FCER1A C TT -/- rs IL-13 C1112T T CC -/- rs RAD50 G AA -/- rs RAD50 T CC -/- rs SOCS-1-820G>T A CC -/- Page 29/44
30 IgG rs FCGR2A A GG -/- rs7483 GSTM3 V224I T CT +/- Page 30/44
31 IgA rs CFH A GG -/- rs HLA G AG +/- rs HLA-DPB2 / COL11A2P A AG +/- rs HLA-DQA2 A GG -/- rs IFIH1 (HLA) C CC +/+ rs IGF1R A GG -/- rs IRF5 A GG -/- rs MTC03P1 C TT -/- rs PSMB8 / TAP1 / TAP2 A GG -/- rs TRAF1 G AG +/- Page 31/44
32 Clotting Factors rs CETP C4402A C AC +/- rs CYP4V2 Q259K C AC +/- rs F A5397C G GG +/+ rs F11 C25264T T CT +/- i F2 (Prothrombin 20210A) A GG -/- Prothrombin 20210A rs6025 F5 Factor V Leiden FVL T CC -/- rs6046 F7 A353G Arg329Gln A GG -/- rs6048 F9 G580A A25386G G AA -/- rs GP6 Pro219Ser G AA -/- rs9898 HRG Pro204Ser T CT +/- rs5918 ITGB3 P1A2/T196C C TT -/- rs KNG I598T GP IIIa HPA-1 T TT +/+ rs NR1I2 C6709A C AA -/- rs SERPINC1 G5301A T TT +/+ Page 32/44
33 Celiac Disease/Gluten Intolerance rs CTLA4 G AG +/- rs HLA G AG +/- rs HLA DQA1 T CC -/- rs HLA-DQA2 A GG -/- Page 33/44
34 Thyroid rs CTLA4 G AG +/- rs FOXE1 A GG -/- rs FOXE1 A AG +/- Page 34/44
35 Eye Health rs BCMO1 C TT -/- rs BCMO1 A379V T CT +/- rs BCMO1 R267S T AA -/- Page 35/44
36 Other Immune Factors rs q27 Region T GG -/- rs APOE ApoE epsilon 4 C TT -/- rs ATG16L1 C CC +/+ rs DMGDH G67591T C AA -/- rs DMGDH T835C A AG +/- rs GAMT C9110T A GG -/- rs GAMT G7497A T CC -/- rs GSDMB T TT +/+ rs HLA-DRB1 G AA -/- rs20541 IL-13 A AG +/- rs IL4R Q576R G AG +/- rs IL5 A AA +/+ i MeFV A744S A CC -/- rs MeFV E148Q G CG +/- i MeFV F479L C GG -/- i MeFV K695R C TT -/- rs MeFV M680I G CC -/- rs MeFV M694I T CC -/- i MeFV M694V C TT -/- rs MeFV P369S A GG -/- i MeFV R761H T CC -/- rs STAT4 G CC -/- rs TNF -238 A GG -/- rs TNF -308 A GG -/- rs TYR (MeFV) V726A A GG -/- Page 36/44
37 Figure 1 Page 37/44
38 Figure 2 Page 38/44
39 Figure 3 Page 39/44
40 Figure 4 Page 40/44
41 Figure 5 Page 41/44
42 Figure 6 Page 42/44
43 Figure 7 Page 43/44
44 Powered by TCPDF ( MTHFRSupport Variant Report v2.1 Figure 8 Page 44/44
ALLERGY/MOLD Gene & Variation rsid # Risk Allele Your Alleles and Results HLA rs7775228 C TT -/- HLA rs2155219 T GG -/-
DETOX CYP1A1*2C A4889G rs1048943 C TT -/- CYP1A1*4 C2453A rs1799814 T GG -/- CYP1A2 C164A rs762551 C AA -/- CYP1B1 L432V rs1056836 C CC +/+ CYP1B1 N453S rs1800440 C TT -/- CYP1B1 R48G rs10012 C no call
plaque reduction assay, modified dye uptake assay including formazan test, dye uptake assay
Sauerbrei A, Bohn-Wippert K, Kaspar M, Krumbholz A, Karrasch M, Zell R. 2015. Database on natural polymorphisms and resistance-related non-synonymous mutations in thymidine kinase and DNA polymerase genes
Computer-based Personal Nutrition Guidance Martin Kohlmeier, MD, PhD
Computer-based Personal Nutrition Guidance Martin Kohlmeier, MD, PhD University of North Carolina at Chapel Hill Department of Nutrition and UNC Nutrition Research Institute mkohlmeier@unc.edu Barriers
Domain Antivirals tested Test methods for phenotype References. Aciclovir (ACV), Foscarnet (FOS) ACV, FOS ACV,
Sauerbrei A, Bohn-Wippert K, Kaspar M, Krumbholz A, Karrasch M, Zell R. 2015. Database on natural polymorphisms and resistance-related non-synonymous mutations in thymidine kinase and DNA polymerase genes
Victims Compensation Claim Status of All Pending Claims and Claims Decided Within the Last Three Years
Claim#:021914-174 Initials: J.T. Last4SSN: 6996 DOB: 5/3/1970 Crime Date: 4/30/2013 Status: Claim is currently under review. Decision expected within 7 days Claim#:041715-334 Initials: M.S. Last4SSN: 2957
Targeted Cancer Gene Analysis For Research Use Only - Not Intended for Clinical Use
Targeted Cancer Gene Analysis For Research Use Only - Not Intended for Clinical Use PGDX ID Sample ID Mutation Position Nucleotide (genomic) Amino Acid (protein) Mutation Type Consequence PGDX2163N_NotchCp
CODES FOR PHARMACY ONLINE CLAIMS PROCESSING
S FOR PHARMACY ONLINE CLAIMS PROCESSING The following is a list of error and warning codes that may appear when processing claims on the online system. The error codes are bolded. CODE AA AB AI AR CB CD
1.- L a m e j o r o p c ió n e s c l o na r e l d i s co ( s e e x p li c a r á d es p u é s ).
PROCEDIMIENTO DE RECUPERACION Y COPIAS DE SEGURIDAD DEL CORTAFUEGOS LINUX P ar a p od e r re c u p e ra r nu e s t r o c o rt a f u e go s an t e un d es a s t r e ( r ot u r a d e l di s c o o d e l a
B I N G O B I N G O. Hf Cd Na Nb Lr. I Fl Fr Mo Si. Ho Bi Ce Eu Ac. Md Co P Pa Tc. Uut Rh K N. Sb At Md H. Bh Cm H Bi Es. Mo Uus Lu P F.
Hf Cd Na Nb Lr Ho Bi Ce u Ac I Fl Fr Mo i Md Co P Pa Tc Uut Rh K N Dy Cl N Am b At Md H Y Bh Cm H Bi s Mo Uus Lu P F Cu Ar Ag Mg K Thomas Jefferson National Accelerator Facility - Office of cience ducation
DetoxiGenomic Profile Patient's Copy
TM DetoxiGenomic Profile Patient: JANE DOE DOB: April 09, 1969 Sex: F MRN: Order Number: Completed: February 26, 2014 Received: February 19, 2014 Collected: February 18, 2014 Security Code: PHASE I Detoxification:
SCO TT G LEA SO N D EM O Z G EB R E-
SCO TT G LEA SO N D EM O Z G EB R E- EG Z IA B H ER e d it o r s N ) LICA TIO N S A N D M ETH O D S t DVD N CLUDED C o n t e n Ls Pr e fa c e x v G l o b a l N a v i g a t i o n Sa t e llit e S y s t e
Detoxification & Your Health
Detoxification & Your Health Detoxification is the metabolic process your body uses to transform and eliminate toxins. The process can occur in two steps, called Phase I and Phase II. Phase I is our first
Detoxification & Your Health
Detoxification & Your Health Detoxification is the metabolic process your body uses to transform and eliminate toxins. The process can occur in two steps, called Phase I and Phase II. Phase I is our first
HR DEPARTMENTAL SUFFIX & ORGANIZATION CODES
HR DEPARTMENTAL SUFFIX & ORGANIZATION CODES Department Suffix Organization Academic Affairs and Dean of Faculty, VP AA 1100 Admissions (Undergraduate) AD 1330 Advanced Ceramics, Colorado Center for--ccac
Addiction Biology REVIEW
357..376 Addiction Biology REVIEW doi:10.1111/j.1369-1600.2010.00287.x Pharmacogenetics of alcohol, nicotine and drug addiction treatments Jessica E. Sturgess 1, Tony P. George 2,3, James L. Kennedy 1,3,
1 D e r 1. S c h u l t a g M a l e a u s. S c h re i b e d e i n e n N a m e n u n t e r e i n K i n d. 1 2 D a s b i n i c h M a l e d i c h s e l b e r. 2 3 F re u n d e M a l e d i c h u n d d e i n
Pharmacogenetic Activities in SWOG Breast Cancer
Pharmacogenetic Activities in SWOG Breast Cancer Pharmacogenomics: Future Plans S8897 Adjuvant CMF vs. CAF/ no Treatment Ambrosone RO1: Other genes (TBCI approved, analyses ongoing) S0221 Adjuvant Dose
Genetic Testing for Mental Health Conditions
MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES CODING APPENDI HISTORY Genetic Testing for Mental Health Conditions Number 12.04.515
C o a t i a n P u b l i c D e b tm a n a g e m e n t a n d C h a l l e n g e s o f M a k e t D e v e l o p m e n t Z a g e bo 8 t h A p i l 2 0 1 1 h t t pdd w w wp i j fp h D p u b l i c2 d e b td S t
Enterprise Data Center A c h itec tu re Consorzio Operativo Gruppo MPS Case S t u d y : P r o g et t o D i sast er R ec o v er y Milano, 7 Febbraio 2006 1 Il G r u p p o M P S L a B a n c a M o n t e d
ELECTRON CONFIGURATION (SHORT FORM) # of electrons in the subshell. valence electrons Valence electrons have the largest value for "n"!
179 ELECTRON CONFIGURATION (SHORT FORM) - We can represent the electron configuration without drawing a diagram or writing down pages of quantum numbers every time. We write the "electron configuration".
Excel Invoice Format. SupplierWebsite - Excel Invoice Upload. Data Element Definition UCLA Supplier website (Rev. July 9, 2013)
Excel Invoice Format Excel Column Name Cell Format Notes Campus* Supplier Number* Invoice Number* Order Number* Invoice Date* Total Invoice Amount* Total Sales Tax Amount* Discount Amount Discount Percent
Summary of State Laws Related to Auto Insurance
Summary of State Laws Related to Auto Insurance Rate Filing Laws for (Prior Form Filing Approval, Use & Laws (Prior File, File & Use, Approval, Use No File, Flex & File, File & Rating) Use, No File) Fault
Genotypes of patients with factor VII deficiency
Genotypes of patients with factor VII deficiency Mutation (Name) -96 C>T IVS4+1 G>A* Location Domain Type Genotype Origin Activity U/dL** Promoter Intron 4 Promoter Regulatory Splicing Antigen U/dL Study
MTHFR and Autism. Help from the Human Genome project. Neil Rawlins, MD Katie Karlson, MD
MTHFR and Autism Help from the Human Genome project. Neil Rawlins, MD Katie Karlson, MD What is Autism, Autism Spectrum disorder, Asperger's, etc? Autism Not a single disease No definitive test available
Attachment "A" - List of HP Inkjet Printers
HP Deskjet 350c Printer HP Deskjet 350cbi Printer HP Deskjet 350cbi Printer w/roller-case HP Deskjet 420 Printer HP Deskjet 420c Printer HP Deskjet 610c Printer HP Deskjet 610cl Printer HP Deskjet 612c
Future Trends in Airline Pricing, Yield. March 13, 2013
Future Trends in Airline Pricing, Yield Management, &AncillaryFees March 13, 2013 THE OPPORTUNITY IS NOW FOR CORPORATE TRAVEL MANAGEMENT BUT FIRST: YOU HAVE TO KNOCK DOWN BARRIERS! but it won t hurt much!
RegulomeDB scores and functional assignments of 153 SCARB1
Table S13. RegulomeDB scores and functional assignments of 153 SCARB1 variants. SNP Chr12 Name a SNP ID b Position c p972 rs181338950 125348548 p1048 insc (1048_ 1049) 125348472 Location Amino Acid Change
H ig h L e v e l O v e r v iew. S te p h a n M a rt in. S e n io r S y s te m A rc h i te ct
H ig h L e v e l O v e r v iew S te p h a n M a rt in S e n io r S y s te m A rc h i te ct OPEN XCHANGE Architecture Overview A ge nda D es ig n G o als A rc h i te ct u re O ve rv i ew S c a l a b ili
Field Value Definitions
ACADEMIC STANDING - TOPS AI 00 - Continuous Enrollment 10 - Officially Resigned 11 - Accelerated - Licensed Practical Nurse CF - Delayed Year First Time Full Time CP - Delayed Year Part Time DO - Degree
I n la n d N a v ig a t io n a co n t r ib u t io n t o eco n o m y su st a i n a b i l i t y
I n la n d N a v ig a t io n a co n t r ib u t io n t o eco n o m y su st a i n a b i l i t y and KB rl iak s iol mi a, hme t a ro cp hm a5 a 2k p0r0o 9f i,e ls hv oa nr t ds eu rmv oedye l o nf dae cr
i n g S e c u r it y 3 1B# ; u r w e b a p p li c a tio n s f r o m ha c ke r s w ith t his å ] í d : L : g u id e Scanned by CamScanner
![i n g S e c u r it y 3 1B# ; u r w e b a p p li c a tio n s f r o m ha c ke r s w ith t his å ] í d : L : g u id e Scanned by CamScanner](/thumbs/24/2864992.jpg "i n g S e c u r it y 3 1B# ; u r w e b a p p li c a tio n s f r o m ha c ke r s w ith t his å ] í d : L : g u id e Scanned by CamScanner")
í d : r ' " B o m m 1 E x p e r i e n c e L : i i n g S e c u r it y. 1-1B# ; u r w e b a p p li c a tio n s f r o m ha c ke r s w ith t his g u id e å ] - ew i c h P e t e r M u la e n PACKT ' TAÞ$Æo
S e w i n g m a c h i n e s for but t - seams. - c o m p l e t e b r o c h u r e -
S e w i n g m a c h i n e s for but t - seams - c o m p l e t e b r o c h u r e - D o h l e s e w i n g m a c h i n e s f o r b u t t - s e a m s Head Office D o h l e m a n u f a c t u re b u t t s e
1. Oblast rozvoj spolků a SU UK 1.1. Zvyšování kvalifikace Školení Zapojení do projektů Poradenství 1.2. Financování 1.2.1.
1. O b l a s t r o z v o j s p o l k a S U U K 1. 1. Z v y š o v á n í k v a l i f i k a c e Š k o l e n í o S t u d e n t s k á u n i e U n i v e r z i t y K a r l o v y ( d á l e j e n S U U K ) z í
U.S. Department of Housing and Urban Development: Weekly Progress Report on Recovery Act Spending
U.S. Department of Housing and Urban Development: Weekly Progress Report on Recovery Act Spending by State and Program Report as of 3/7/2011 5:40:51 PM HUD's Weekly Recovery Act Progress Report: AK Grants
Breaking Barriers in the Genomics and Pharmacogenetics of Drug Addiction
nature publishing group state Breaking Barriers in the Genomics and Pharmacogenetics of Drug Addiction MK Ho 1, D Goldman 2, A Heinz 3, J Kaprio 4, MJ Kreek 5, MD Li 6, MR Munafò 7 and RF Tyndale 1 Drug
DATING YOUR GUILD 1952-1960
DATING YOUR GUILD 1952-1960 YEAR APPROXIMATE LAST SERIAL NUMBER PRODUCED 1953 1000-1500 1954 1500-2200 1955 2200-3000 1956 3000-4000 1957 4000-5700 1958 5700-8300 1959 12035 1960-1969 This chart displays
Listado unitario de SNPs
2010 Listado unitario de SNPs EUGENOMIC 05/10/2010 EUGENOMIC, ofrecer la determinación de unos 200 SNP de forma unitaria, es decir la posibilidad de personalizar para cad problema en cada paciente los
CROSS REFERENCE. Cross Reference Index 110-122. Cast ID Number 110-111 Connector ID Number 111 Engine ID Number 112-122. 2015 Ford Motor Company 109
CROSS REFERENCE Cross Reference Index 110-122 Cast ID Number 110-111 Connector ID Number 111 112-122 2015 Ford Motor Company 109 CROSS REFERENCE Cast ID Number Cast ID Ford Service # MC Part # Part Type
MORPHEUS. http://biodev.cea.fr/morpheus/ Prediction of Transcription Factors Binding Sites based on Position Weight Matrix.
MORPHEUS http://biodev.cea.fr/morpheus/ Prediction of Transcription Factors Binding Sites based on Position Weight Matrix. Reference: MORPHEUS, a Webtool for Transcripton Factor Binding Analysis Using
High School Mathematics: State-Level Curriculum Standards and Graduation Requirements
High School Mathematics: State-Level Curriculum Standards and Graduation Requirements Prepared By: Barbara J. Reys Shannon Dingman Nevels Nevels Dawn Teuscher Center for the Study of Mathematics Curriculum
m Future of learning Zehn J a hr e N et A c a d ei n E r f o l g s p r o g r a m Cisco E x p o 2 0 0 7 2 6. J u n i 2 0 0 7, M e sse W ie n C. D or n in g e r, b m u k k 1/ 12 P r e n t t z d e r p u t
All answers must use the correct number of significant figures, and must show units!
CHEM 10113, Quiz 2 September 7, 2011 Name (please print) All answers must use the correct number of significant figures, and must show units! IA Periodic Table of the Elements VIIIA (1) (18) 1 2 1 H IIA
W Cisco Kompetanse eek end 2 0 0 8 SMB = Store Mu ll ii gg hh eter! Nina Gullerud ng ulleru@ c is c o. c o m 1 Vår E n t e r p r i s e e r f a r i n g... 2 S m å o g M e llo m s t o r e B e d r i f t e
I Have...Who Has... Multiplication Game
How to play the game: Distribute the cards randomly to your students. Some students may get more than one card. Select a student to begin by reading their card aloud. (example: 35. who has 4x4?) 35 4 x
Thrombophilia. Steven R. Lentz, M.D. Ph.D. Carver College of Medicine The University of Iowa May 2003
Thrombophilia Steven R. Lentz, M.D. Ph.D. Carver College of Medicine The University of Iowa May 2003 Thrombophilia Hereditary and acquired risk factors for thrombosis Venous thromboembolism Arterial thromboembolism
Application Note: Cisco A S A - Ce r t if ica t e T o S S L V P N Con n e ct ion P r of il e Overview: T h i s a p p l i ca ti o n n o te e x p l a i n s h o w to co n f i g u r e th e A S A to a cco m
Payroll System Codes
Page 1 of 6 Payroll System Codes Status Codes User Guide Section: 200-8 Screen: PF.PS.STAT.U A IA IC IN IP IW LP LR LS LW NA NE PA PG PP PR RP RW SC SP T TP Active Inactive for one tax quarter Inactive
HIGH DENSITY DATA STORAGE IN DNA USING AN EFFICIENT MESSAGE ENCODING SCHEME Rahul Vishwakarma 1 and Newsha Amiri 2
HIGH DENSITY DATA STORAGE IN DNA USING AN EFFICIENT MESSAGE ENCODING SCHEME Rahul Vishwakarma 1 and Newsha Amiri 2 1 Tata Consultancy Services, India derahul@ieee.org 2 Bangalore University, India ABSTRACT
Electronegativity and Polarity
and Polarity N Goalby Chemrevise.org Definition: is the relative tendency of an atom in a molecule to attract electrons in a covalent bond to itself. is measured on the Pauling scale (ranges from 0 to
A Quick Guide to Colleges. Offering Engineering Degrees
Qk gs ffg gg Dgs Fby 2007 www.dgs.g Qk gs ffg gg Dgs Ts qk f g ps sy sg (by s) f U.S. gs ss ffg b s (4-y) gs gg 363 ss, spg 50 ss ps Ds f b R. Ts sy s s gg g pgs by f gg Tgy (T, gz f g sy pgs pp s, pg,
Chem 115 POGIL Worksheet - Week 4 Moles & Stoichiometry Answers
Key Questions & Exercises Chem 115 POGIL Worksheet - Week 4 Moles & Stoichiometry Answers 1. The atomic weight of carbon is 12.0107 u, so a mole of carbon has a mass of 12.0107 g. Why doesn t a mole of
CLASS TEST GRADE 11. PHYSICAL SCIENCES: CHEMISTRY Test 6: Chemical change
CLASS TEST GRADE PHYSICAL SCIENCES: CHEMISTRY Test 6: Chemical change MARKS: 45 TIME: hour INSTRUCTIONS AND INFORMATION. Answer ALL the questions. 2. You may use non-programmable calculators. 3. You may
MATCH Commun. Math. Comput. Chem. 61 (2009) 781-788
MATCH Communications in Mathematical and in Computer Chemistry MATCH Commun. Math. Comput. Chem. 61 (2009) 781-788 ISSN 0340-6253 Three distances for rapid similarity analysis of DNA sequences Wei Chen,
Federation of State Boards of Physical Therapy Jurisdiction Licensure Reference Guide Topic: Continuing Competence
This document reports CEU (continuing education units) and CCU (continuing competence units) requirements for renewal. It describes: Number of CEUs/CCUs required for renewal Who approves continuing education
Personalized medicine, also known as precision
PRINTER-FRIENDLY VERSION AVAILABLE AT PAINMEDICINENEWS.COM Personalized Pain Medicine: Pharmacogenetic Testing for Pain and Opioid Addiction INNA BELFER, MD, PHD Adjunct Professor Departments of Medicine
Earthquake Hazard Zones: The relative risk of damage to Canadian buildings
Earthquake Hazard Zones: The relative risk of damage to Canadian buildings by Paul Kovacs Executive Director, Institute for Catastrophic Loss Reduction Adjunct Research Professor, Economics, Univ. of Western
Arboviral Surveillance Results
Arboviral Surveillance Results Start Date: End Date: Trap Location Trap Date Trap Type Date Tested Pool No. Mosquito Species Pool Size Results Assay Bexley Test Results Bexley 6/10/2013 Gravid Trap 6/11/2013
d e f i n i c j i p o s t a w y, z w i z a n e j e s t t o m. i n. z t y m, i p o jі c i e t o
P o s t a w y s p o і e c z e t s t w a w o b e c o s у b n i e p e і n o s p r a w n y c h z e s z c z e g у l n y m u w z g lb d n i e n i e m o s у b z z e s p o і e m D o w n a T h e a t t i t uodf
C e r t ifie d Se c u r e W e b
C r t ifi d S c u r W b Z r t ifizi r t Sic h r h it im W b 1 D l gat s N ic o las M ay n c o u r t, C EO, D r am lab T c h n o lo gi s A G M ar c -A n d r é B c k, C o n su lt an t, D r am lab T c h n
Lessons Learned from Carrier Screening: Cystic Fibrosis The Parent s s Perspective
Lessons Learned from Carrier Screening: Cystic Fibrosis The Parent s s Perspective Martin Kharrazi, Ph.D. Genetic Disease Screening Program California Department of Public Health Population-based Carrier
MyOWNMcMaster Degree Pathway: Diploma in Business Administration & Bachelor of Arts in History
MyOWNMcMaster Degree Pathway: Diploma in Business Administration & Bachelor of Arts in History Requirements The MyOWNMcMaster degree pathway has three parts: diploma, elective and undergraduate courses.
Transient Voltage Suppressor SMBJ5.0 - SMBJ440CA
Features: Glass passivated junction Low incremental surge resistance, excellent clamping capability 600W peak pulse power capability with a 10/1,000μs waveform, repetition rate (duty cycle): 0.01% Very
BIG DATA IN TRANSPORT RESEARCH: LEGAL AND PRIVACY CHALLENGES
BIG DATA IN TRANSPORT RESEARCH: LEGAL AND PRIVACY CHALLENGES P R E S ENTATION T R A F I KF DOR A GE MEETING 2 0 1 5 AALBORG 29 TH OF AUGUST NT K R I S T I A N H E G N E R R E I N A U, K R I SJ TO IHA N
Requirements The MyOWNMcMaster degree pathway has three parts: diploma, elective and undergraduate courses.
MyOWNMcMaster Degree Pathway: Diploma in Business Administration with a Concentration in Marketing & Bachelor of Arts in History Requirements The MyOWNMcMaster degree pathway has three parts: diploma,
english parliament of finland
gh f fd 2012 P cvd f h f y f h g Mdy, 6 Fby 2012. A h d MP, K T hd h ch h c f h S. E H (Sc Dcc Py) w -cd S, P Rv (N C Py) F Dy S d A Jh (F Py) Scd Dy S. Th g c c Tdy, 7 Fby, whch Pd f h Rbc Tj H d P f
The MyOWNMcMaster degree pathway has three parts: diploma, elective and undergraduate courses.
MyOWNMcMaster Degree Pathway: Diploma in Human Resources Management & Bachelor of Arts in History Requirements The MyOWNMcMaster degree pathway has three parts: diploma, elective and undergraduate courses.
NAAUSA Security Survey
NAAUSA Security Survey 1. How would you rate the importance of each of the following AUSA security improvements. Very important Somewhat important Not too important Not at all important Secure parking
Targeted Learning with Big Data
Targeted Learning with Big Data Mark van der Laan UC Berkeley Center for Philosophy and History of Science Revisiting the Foundations of Statistics in the Era of Big Data: Scaling Up to Meet the Challenge
The Business Case for D om aink ey s I d ent ified M ail Andy Spillane V ic e P r es ident, Y ah o o! M February 13, 2006 ail 1 Fighting Spam & Email Abuse R eq uir es a M ulti-fac eted Appr o ac h DomainKeys
SCHOOL PESTICIDE SAFETY AN D IN TEG R ATED PEST M AN AG EM EN T Statutes put into law by the Louisiana Department of Agriculture & Forestry to ensure the safety and well-being of children and school personnel
Maternal hyperglycemia and foetal epigenetic adaptations
Note: for non-commercial purposes only Maternal hyperglycemia and foetal epigenetic adaptations Marie-France Hivert, MD, MMSc Harvard Pilgrim Health Care Institute, Department of Population Medicine Harvard
100% ionic compounds do not exist but predominantly ionic compounds are formed when metals combine with non-metals.
2.21 Ionic Bonding 100% ionic compounds do not exist but predominantly ionic compounds are formed when metals combine with non-metals. Forming ions Metal atoms lose electrons to form +ve ions. Non-metal
From Quantum to Matter 2006
From Quantum to Matter 006 Why such a course? Ronald Griessen Vrije Universiteit, Amsterdam AMOLF, May 4, 004 vrije Universiteit amsterdam Why study quantum mechanics? From Quantum to Matter: The main
OPENBARE ZITTING 1. U ni f o r m e a l g e m e ne p o l i t i e v e r o r d e ni ng e n p u nc t u e l e i m p l e m e nt a t i e GAS ( g e m e e nt e l i j k e a d m i ni s t r a t i e v e s a nc t i
Long-QT syndrome (LQTS) is a cardiovascular disorder
Spectrum of Mutations in Long-QT Syndrome Genes KVLQT1, HERG, SCN5A, KCNE1, and KCNE2 Igor Splawski, PhD; Jiaxiang Shen, MS; Katherine W. Timothy, BS; Michael H. Lehmann, MD; Silvia Priori, MD, PhD; Jennifer
Empire BlueCross BlueShield Professional Reimbursement Policy
Subject: Modifier Rules NY Policy: 0017 Effective: 02/01/2014 06/30/2014 Coverage is subject to the terms, conditions, and limitations of an individual member s programs or products and policy criteria
Chem 115 POGIL Worksheet - Week 4 Moles & Stoichiometry
Chem 115 POGIL Worksheet - Week 4 Moles & Stoichiometry Why? Chemists are concerned with mass relationships in chemical reactions, usually run on a macroscopic scale (grams, kilograms, etc.). To deal with
Vehicle Identification Numbering System 00.03
Vehicle Identification Numbering System 00.03 IMPORTANT: See Subject 050 for the vehicle identification numbering system for vehicles built before May 1, 2000. Federal Motor Vehicle Safety Standard 115
Using Predictive Modeling to Reduce Claims Losses in Auto Physical Damage
Using Predictive Modeling to Reduce Claims Losses in Auto Physical Damage CAS Loss Reserve Seminar 23 Session 3 Private Passenger Automobile Insurance Frank Cacchione Carlos Ariza September 8, 23 Today
New York Public School Spending In Perspec7ve
New York Public School Spending In Perspec7ve School District Fiscal Stress Conference Nelson A. Rockefeller Ins0tute of Government New York State Associa0on of School Business Officials October 4, 2013
T360 Barbecue. Assembly Manual. 85-3052-6 (G30531) Propane 1 YEAR LIMITED WARRANTY
T360 Barbecue Assembly Manual 85-3052-6 (G30531) Propane 1 YEAR LIMITED WARRANTY READ AND SAVE MANUAL FOR FUTURE REFERENCE. If pre-assembled, leave this manual with unit for consumer s future reference.
Federation of State Boards of Physical Therapy Jurisdiction Licensure Reference Guide Topic: License Renewal Who approves courses?
Federation of State s of Physical The table below provides information on approval of continuing education/competence courses and for each jurisdiction. Summary Number of jurisdictions requiring approval
The Lincoln National Life Insurance Company Variable Life Portfolio
The Lincoln National Life Insurance Company Variable Life Portfolio State Availability as of 12/14/2015 PRODUCTS AL AK AZ AR CA CO CT DE DC FL GA GU HI ID IL IN IA KS KY LA ME MP MD MA MI MN MS MO MT NE
Organic Pigments. Azo Pigments
Organic Pigments Azo Pigments Holtint Fast Yellow G Yellow 1 Holtint Fast Yellow 10 G Yellow 3 Holtint Fast Yellow 5G Yellow 5 Holtint Diaryl Yellow DHG Yellow 12 Holtint Diaryl Yellow GR Yellow 13 Holtint
Your Touchstone Energy Cooperative. Mountrail-Williams Electric Cooperative
NOVEMBER 2015 Y T Egy Cv Y T Egy Cv Y T Egy Cv Y T Egy Cv M-Wm E Cv Y T Egy Cv Y T Egy Cv WHITE WHITE WILLISTON 577-3765 STANLEY 628-2242 NEW TOWN 627-3550 Hy y! Hy Tkgvg fm M-Wm E Cv b ff.m.m MOUNTRAIL-WILLIAMS
Population Pharmacokinetics of Atazanavir in Naïve HIV Infected Patients using Medication Events Monitoring System (MEMS) for drug intake timing
Population Pharmacokinetics of Atazanavir in Naïve HIV Infected Patients using Medication Events Monitoring System (MEMS) for drug intake timing ANRS -COPHAR clinical trial Céline Verstuyft Pharmacologie,
GENEWIZ, Inc. DNA Sequencing Service Details for USC Norris Comprehensive Cancer Center DNA Core
DNA Sequencing Services Pre-Mixed o Provide template and primer, mixed into the same tube* Pre-Defined o Provide template and primer in separate tubes* Custom o Full-service for samples with unknown concentration
MS IN EARLY CHILDHOOD STUDIES
MS IN EARLY CHILDHOOD STUDIES Child Development (CD) C D001 - T h eo r ies of C h i ld D eve l opm e nt Demo ns t rate a n understand i ng of theories and concepts o f ch ild deve lo pme nt. C D002 - K
Transfer Equivalency Table
AC 114 ACCT 201 ACCT 221 MGMT 202 ACCT 2300 ACCT 2301 AC 124 ACCT 202 ACCT 222 MGMT 303* ACCT 2301 ACCT 2302 AC 213 ACCT elective Elective MGMT Elective ACCT 2- - - (transfers) AC 213A ACCT elective MGMT
Broadband Technology Opportunities Program: Sustainable Broadband Adoption and Public Computer Centers
Broadband Technology Opportunities Program: Sustainable Broadband Adoption and Public Computer Centers National Telecommunications and Information Agency (NTIA) U. S. Department of Commerce Funded by the
Federation of State Boards of Physical Therapy Jurisdiction Licensure Reference Guide Topic: Continuing Competence
This document reports CEU requirements for renewal. It describes: Number of required for renewal Who approves continuing education Required courses for renewal Which jurisdictions require active practice
Ga Home Finance. payday loans in miami. online bad credit personal loans. 100day payday loans. cash advance boise idaho
Ga Home Finance payday loans in miami online bad credit personal loans 100day payday loans cash advance boise idaho safe cash installment loans no credit check payday guaranteed approval top online ohio
Note: This App is under development and available for testing on request. Note: This App is under development and available for testing on request. Note: This App is under development and available for
A n d r e w S P o m e r a n tz, M D
T e le h e a lth in V A : B r in g in g h e a lth c a r e to th e u n d e r s e r v e d in c lin ic a n d h o m e A n d r e w S P o m e r a n tz, M D N a tio n a l M e n ta l H e a lth D ir e c to r f
Approaches to Integrating Next Generation Sequencing into the Electronic Health Record
AMIA Webinar April 16, 2014 Approaches to Integrating Next Generation Sequencing into the Electronic Health Record Peter Tarczy-Hornoch, University of Washington On behalf of the Clinical Sequencing Exploratory
/* ------------------------------------------------------------------------------------
Pr o g r a m v a r e fo r tr a fik k b e r e g n in g e r b a s e r t p å b a s is k u r v e m e to d e n n M a tr ix * x M a tr ix E s ta lp h a B e ta ; n M a tr ix * z M a tr ix ; g e n M a tr ix X